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I.  INTRODUCTION 
Over the past two decades, and to a greater extent recently, society has been 
increasingly exposed to prescription drug advertisements aimed directly at the 
consumer.  The industry’s gradual shift in focus from “physician-directed” to 
“consumer-directed” advertisements poses a threat to the public health because it 
may have the effect of misleading consumers by understating a drug’s adverse 
reactions and overstating the benefits. 
The increase in consumer-directed advertising has helped to foster a health care 
atmosphere in which it is the patient, and not the medical practitioner, who initiates a 
discussion regarding possible drug therapy.2  Consumer-directed advertising also has 
a profound impact on the doctor-patient relationship and results in patients 
consuming drugs with attractive benefits and undisclosed possible adverse reactions.  
This creates an increased dependence on prescription drugs, and the falsified notion 
that there is a prescription drug to cure most any condition.3  The effects that 
consumer-directed advertising of prescription drugs have on the health care system 
warrant a thorough review and modification of the existing United States Food and 
Drug Agency (FDA) regulations in order to preserve the public health.4 
To date, the FDA regulations have remained unresponsive to this change in 
advertising focus.  In a draft guidance5 issued by the FDA, the agency has actually 
made advertising of prescription drugs easier by making disclosure requirements of 
                                                                
2
See Bette-Jane Crigger, Ask Your Doctor or Pharmacist, HASTINGS CENTER REP., Mar.-
Apr. 1998, at 47 (stating that prescription drug advertisements are simplistic and misleading, 
nurturing unrealistic expectations of benefit that physicians will not be able to counter 
effectively, and that this tension adds to the already fraying doctor-patient relationship when 
patients demand the medications they have seen advertised); Michie Hunt, Direct-to-
Consumer Advertising of Prescription Drugs, NAT’L HEALTH POL’Y F., (Apr. 1998) (noting 
that most physicians are accommodating to patient drug requests). 
3
In a recent survey, more than 40,000 consumers confirmed that prescription drug 
advertising had changed the way they took care of medical problems.  See Abigail Zuger, 
Drug Companies’ Sales Pitch: ‘Ask Your Doctor,’ N.Y. TIMES, Aug. 5, 1997, at C2.  See also 
Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council, 425 U.S. 748 (1976).  
In his dissent, Justice Rehnquist noted that the general advertising of drugs may lead to the 
notion that there is a drug for every ill, whether real or imaginary.  Virginia State Bd. of 
Pharmacy, 425 U.S. at 790. 
4
See, Prescription Drug Product Labeling; Medication Guide Requirements, 60 Fed. Reg. 
44,182 (1995) (to be codified at 21 C.F.R. pts. 201, 208, 314, 601) (proposed Aug. 24, 1995). 
The FDA believes that “inadequate access to appropriate patient information is a major cause 
of inappropriate use of prescription medications, resulting in serious personal injury and 
related costs to the health care system.”  Id.  The FDA has proposed performance standards to 
define the acceptable levels of information distribution and quality that accompanies 
prescription drugs.  Id.  However, these standards do not affect prescription drug advertising.  
Id. 
5
Draft guidances are FDA documents that represent the agency’s current thinking on a 
particular subject.  See 21 U.S.C. § 371(h)(1)(A) (1999).  They do not create or confer any 
rights, and are not binding on the FDA or the public.  Id. 
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adverse drug reactions6 less stringent for broadcast advertisements.  The current 
regulatory system in place by the FDA7 is inadequate to deal with current issues 
surrounding consumer-directed advertising.  This is due in large part because the 
regulations currently in effect were implemented in 1938 before the advent of this 
new breed of advertising.8  There is no doubt that the nature of advertising has 
changed significantly since that time and an updated version of regulations is needed 
to protect the public. 
Consumers’ quest for and access to information has been accompanied by an 
increase in the patient’s role in his or her health care treatment.9  Prescription drug 
advertisements directed to the consumer have the potential to be excellent sources of 
consumer information and should therefore not be banned outright.10  Greater access 
to patient information certainly enables the patient to take a more active role in their 
treatment. 
The public health problems discussed in this Paper are undoubtedly caused by a 
number of concurrently occurring problems.  The solution set out here is to construct 
a more stringent FDA regulatory scheme which seeks to minimize this problem, 
while acknowledging that it will not eliminate it. 
This Paper will evaluate the effectiveness of the current FDA regulatory scheme 
regarding consumer-directed prescription drug advertising.  Part II discusses the 
relevant history of consumer-directed advertising of prescription drugs which is a 
relatively new practice in the United States.  Possible explanations are reviewed for 
why the change in focus from physicians to consumers as the targets of such 
advertising has occurred. 
Part III explains the major classifications of consumer-directed advertising that 
the FDA has categorized and examines the differences existing among them. 
Part IV focuses on the current FDA regulatory scheme and begins to expose 
some of the difficulties of applying the current regulations to consumer-directed 
advertisements. 
                                                                
6
WORLD HEALTH ORGANIZATION, TECHNICAL REPORT SERIES NO. 425, INTERNATIONAL 
DRUG MONITORING:  THE ROLE OF THE HOSPITAL 6 (1969).  According to the World Health 
Organization (WHO), an adverse drug reaction is any noxious, unintended, and undesired 
effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy.  
Id.  This paper will not focus on contraindications (patients who should definitely not take a 
particular drug product) because they typically represent a more bright-line standard in risk 
decision-making. 
7
One of the primary functions of the FDA is to regulate prescription drugs, and 
particularly prescription drug advertising.  See 21 U.S.C. § 321 (1999).  The FDA has sole 
jurisdiction of prescription drug advertisement regulation, while the Federal Trade 
Commission (FTC) has jurisdiction over OTC drugs.  Id. 
8
Id.  The Federal Food, Drug and Cosmetic Act was enacted in 1938.  Id. 
9
Consumers can learn from advertising that all drugs (even over the counter drugs) have 
side effects.  See John E. Calfee, How Advertising Informs to our Benefit, CONSUMERS’ RES. 
MAG., Apr. 1998, at 13. 
10
Consumer-directed advertising of prescription drugs is still prohibited in Canada and 
most of Western Europe.  See Crigger, supra note 2, at 47. 
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Part V explores specific effects the FDA regulations have on our current 
healthcare system.  These include:  (1) downplayed adverse drug reactions; (2) 
inconsistent scope and quantity of adverse drug reactions advertised; (3) the 
increased cost to society; (4) deterrence; and (5) increased strain on the doctor-
patient relationship. 
Recommendations for effectively strengthening the FDA regulations are included 
in Part VI.  These include a standardized percentage over which all adverse reactions 
must be reported to provide uniformity in the industry and to allow consumer 
comparison.  In addition, all prescription drug advertisements should be in terms 
easily understood by the ordinary consumer.  An illustration is included to 
demonstrate the proposed effectiveness of such increased regulation. 
This Paper concludes that the time has come for the FDA to consider updating or 
amending the current regulations that affect advertising of prescription drugs, 
particularly those advertisements which are directed at consumers. 
II.  HISTORY OF CONSUMER-DIRECTED ADVERTISING 
Drug manufacturers have “advertised” their products since the industry’s 
inception.  Until the early 1980’s, however, drug manufacturers primarily relied 
upon promoting their products directly to medical practitioners.11  This was in the 
form of scientific literature, mailings, and visits by representatives to speak directly 
to the practitioner.12  These methods are still used today in conjunction with 
consumer-directed advertising. 
Consumer-directed advertising first began to occur in response to a Federal 
Register notice in 1985 which stated that current regulations governing prescription 
drug advertising provide sufficient safeguards to protect consumers.13  The Agency, 
in effect, indicated that existing standards created to regulate marketing of drugs to 
physicians would apply to consumer-directed advertising also.14  Thus, the FDA did 
not enact any specific regulations or requirements pertaining solely to consumer-
directed advertising. 
A possible explanation for the change in focus from prescribers to consumers 
may be due to the advent of managed care organizations.15  Many managed care 
entities such as health maintenance organizations (HMOs) have put consumer 
restrictions on access to certain prescriptions.16  Thus, through the use of drug 
formularies, due to direct contracts between HMOs and manufacturers, many 
patients and doctors are effectively denied a possible treatment because of payment 
                                                                
11Hunt, supra note 2, at 3. 
12Id. 
13
Direct-to-Consumer Advertising of Prescription Drugs; Withdrawal of Moratorium, 50 
Fed. Reg. 36,677 (1985).  This lifted a voluntary moratorium placed on the industry by the 
FDA from the time consumer-directed advertising was pondered until the agency could 
research its likely effects.  Id. 
14
See Hunt, supra note 2, at 3. 
15
Id. at 5. 
16
Id. (noting that this is especially true when a manufacturer is introducing a drug that 
cannot demonstrate significant therapeutic advances or cost savings over existing therapies). 
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restrictions.  For example, doctors prescribing medications for patients in certain 
HMOs may have the option of only one or two drugs in a particular therapeutic class, 
instead of the full range of available drugs on the market.   The resultant shift in 
marketing focus by the manufacturers has enabled pharmaceutical companies to 
regain control of the prescription drug market.17 
Consumer-directed advertising began primarily in the print medium because of 
the ease with which advertisers could comply with FDA labeling requirements.18  As 
a practical matter, under current FDA regulations, there is no difference between a 
print advertisement in a physician’s journal and a popularly circulated entertainment 
magazine. 
More recently, manufacturers have tapped into the enormous market of broadcast 
advertising to promote their drug products.19  These advertisements are typically 
several-minute commercials on television and, to a lesser extent, on radio.  Here, the 
FDA has issued a recent draft guidance20 to instruct manufacturers on how they may 
comply best with existing regulations for drug advertising and how to apply them to 
broadcast advertising. 
The computer realm of advertising on the World Wide Web seems to be the next 
target for drug manufacturers.  The Internet poses many of the same issues 
surrounding print advertising with the additional dynamic of rapidly changing 
technology.21 
III.  TYPES OF CONSUMER-DIRECTED ADVERTISING 
The FDA has classified consumer-directed advertising in three categories:  (1) 
“product-claim” containing safety and efficacy statements; (2) “help-seeking” 
containing information about a condition and recommending that the consumer 
consults a medical practitioner (while not mentioning the name of the drug or 
                                                                
17
Id. 
18
“Labeling” includes all written, printed, or graphic materials accompanying a regulated 
product.  See 21 U.S.C. § 321(m) (1999).  The Supreme Court has stated that this definition is 
not limited to information physically accompanying a product and that the textual relationship 
between the materials and the product is fundamental.  Kordel v. United States, 335 U.S. 345, 
349-50 (1948). 
19
One manufacturer has recently experimented with a celebrity spokesperson.  Schering-
Plough used former Good Morning America host Joan Lunden to promote the fast-acting 
Claritin RediTabs allergy medication.  See Melanie Wells, Despite Star Power, Claritin Ads 
Falter, USA TODAY, Sep. 28, 1998, at 8B.  Consumer analyst corporation Ad Track has 
reported that it is among the least-liked consumer advertising campaigns since it began 
measuring prescription drug advertisements in 1995.  Id. 
20
See Draft Guidance for Industry; Consumer-Directed Broadcast Advertisements; 
Availability, 62 Fed. Reg. 43,171 (1997). 
21
See David W. Opderbeck, How Should FDA Regulate Prescription Drug Promotion on 
the Internet?, 53 FOOD DRUG L.J. 47, 60 1998 (addressing the unique problems raised by 
proposed regulation of prescription drug labeling and advertising on the Internet.  For 
example, is a banner advertisement considered a “reminder advertisement” even though it is 
linked to a broader homepage?). 
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treatment); and (3) “reminder” containing the drug name and limited information, 
while excluding all representations about the drug. 22 
A.  Product Claim 
Product claim advertisements contain safety and efficacy claims about a specific 
prescription drug product.23  These advertisements are limited to one specific drug 
product and currently have not compared drugs, or classes of drugs, with each 
other.24  Proponents of this noncomparative format argue that consumers do not have 
the contextual knowledge to evaluate such comparative claims.25  Opponents contend 
that consumers can evaluate comparative claims that present a fair balance between 
benefits and adverse reactions.26 
B.  Help-Seeking 
Help-seeking advertisements encourage consumers with particular symptoms, 
conditions, or diseases to consult their doctor to discuss general treatment options, 
but do not mention the name of any specific drug products.27  If there is only one 
available treatment for a condition, help-seeking advertisements may not be used 
because, by implication, they would be advertising for the product.28  In such an 
instance, the FDA would regulate the help-seeking materials as product claim 
materials.29 
The FDA does not currently regulate help-seeking materials.  Opponents to this 
stance feel that consumers are able to link a sponsoring manufacturer to a specific 
prescription drug.30 
C.  Reminder 
Reminder advertisements merely reinforce name recognition and brand loyalty.31  
These advertisements have been traditionally targeted toward prescribers in an effort 
to increase the number of prescriptions by increasing the frequency that a prescriber 
recalls a drug’s name and its clinical function.32 
                                                                
22
Direct-to-Consumer Promotion; Public Hearing, 60 Fed. Reg. 42,581, 42,482 (1995). 
23
Id. 
24
Id. 
25
Id. 
26
Id. 
27
Id. 
28
Direct-to-Consumer Promotion; Public Hearing, 60 Fed. Reg. at 42,582. 
29
Id. 
30
Id. 
31
Direct-to-Consumer Promotion; Public Hearing, 60 Fed. Reg. 42,583. 
32
Id. 
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The effect that reminder advertisements have on consumers has not yet been 
established since consumers are less likely to associate the clinical function of a drug 
and its brand name.33 
IV.  THE CURRENT FDA REGULATION OF CONSUMER-DIRECTED ADVERTISING 
As previously stated, the FDA has set forth one set of regulations for all 
prescription drug advertising.34  There are three provisions of (the Code of Federal 
Regulations) section 202.1(e) of concern here: (1) the “brief summary” provision; (2) 
the “major statement” provision; and (3) the “adequate provision.” 
A.  The “Brief Summary” Provision 
The regulations require all advertisements for any prescription drug to present “a 
true statement of information in brief summary relating to side effects, 
contraindications, and effectiveness.”35  This is consistent with the Federal Food, 
Drug, and Cosmetic Act36 which also requires advertisements to contain 
“information in brief summary relating to side effects, contraindications, and 
effectiveness.”37 
The provisions in section 202.1(e)(1) seem to conflict with other provisions of 
the same section.  In section 202.1(e)(3), the regulations require that “information 
relating to side effects and contraindications shall disclose each specific side effect 
and contraindication contained in required, approved, or permitted labeling for the 
advertised drug dosage form(s).”38  Advertisements in print medium have adhered to 
this more stringent requirement by including in an advertisement a copy of the 
official drug labeling.  However, the presence of this information is not enough.  The 
public health is not benefited by fine-printed labeling in highly scientific terms.  
Adverse event information is rendered effectively useless when surrounded by 
pharmacologic information such as metabolism and excretion, which the average 
consumer can not comprehend.  Further, the accompanying product labeling 
frequently appears on the reverse side of the page of the original advertisement.39  
                                                                
33
Id.  But cf. Zuger, supra note 3, at C2 (stating that there is some evidence that patients 
are fertile ground for cultivating brand awareness in the ever more competitive pharmaceutical 
market). 
34
See 21 C.F.R. § 202.1 (1999). 
35
See id. § 202.1(e)(i) (“When used in this section ‘side effects, contraindications’ include 
side effects, warnings, precautions, and contraindications and include any such information 
under such headings as cautions, special considerations, important notes, etc.”). 
36
See 21 U.S.C. § 301 (1999). 
37
See 21 U.S.C. § 352(n) (1999). 
38
See 21 C.F.R. § 202.1(e)(3)(iii). 
39
The FDA regulations classify an advertisement as false, lacking in fair balance, or 
otherwise misleading if (1) it “fails to provide adequate emphasis for the fact that two facing 
pages are part of the same advertisement when one page contains information relating to side 
effects and contraindications,” or (2), if it “fails to include on each page or spread of an 
advertisement the information relating to side effects and contraindications or a prominent 
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This too renders it useless since a page-turning consumer is unlikely to even realize 
that a page of black and white text is intimately connected to a glossy color 
advertisement on another page.40  The end result is that a consumer is unlikely to 
even attempt to read this detailed information. 
B.  The “Major Statement” Provision 
The “major statement” provision is an instance in which the FDA has recognized 
a difference between print and broadcast advertising.  This obvious difference is that 
it would be nearly impossible to name all of a drug’s potential adverse reactions in a 
one minute broadcast advertisement, while at the same time it would be very easy 
and misleading to scroll the list of adverse reactions on a television screen.  It is 
doubtful that either option would benefit the consumer or give effect to the FDA’s 
intentions.  The regulations state that “advertisements broadcast through media such 
as radio, television, or telephone communications systems shall include information 
relating to the major side effects and contraindications of the advertised drugs in the 
audio or audio and visual parts of the presentation.”41  Thus, a broadcast 
advertisement may not simply scroll or flash a list of potential adverse reactions on 
the television screen. 
C.  The “Adequate Provision” Requirement for Broadcast Advertisements 
The “adequate provision” requirement is, in effect, an alternative for broadcast 
advertisers.  It allows the manufacturer to avoid the “major statement” provision if 
“adequate provision is made for dissemination of the approved or permitted package 
labeling in connection with the broadcast presentation [and] shall contain a brief 
summary of all necessary information relat[ing] to side effects and 
contraindications.”42  The most notable industry example is the usage of toll-free 
telephone numbers which the consumer may call to get the required drug 
information. 
The FDA has stated that this provision can be met by providing an effective 
mechanism by which the majority of a potentially diverse audience can receive the 
product’s approved labeling.43  However, this audience will inevitably include 
persons with limited access to technologically sophisticated outlets (e.g., Internet 
access and personal fax machines) and persons who hesitate to actively request 
additional product information.44  The FDA recommends including the following 
mechanisms to communicate to these patients: 
                                                          
reference to its presence and location when it is presented as a distinct part of an 
advertisement.”  21 C.F.R. § 202.1 (e)(7)(ix), (xii). 
40
See Editorial, Pushing Ethical Pharmaceuticals Direct to the Public, 351 LANCET 921 
(1998) (stating that the closely packed black and white listing of drug information following a 
colorful print advertisement will not likely be read).  
41
See 21 C.F.R. § 202.1(e)(1). 
42
Id. 
43
Draft Guidance for Industry; Consumer-Directed Broadcast Advertisements; 
Availability, 62 Fed. Reg. at 43,171. 
44
See id. 
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1.  The Toll-Free Telephone Number 
The toll-free telephone number is acceptable to the FDA as long as the caller is 
given the choice of having the information read to them over the phone or sent to 
them in a timely manner by fax or mail.45  
The logic here is faulted because it is unlikely that a person who would not 
otherwise seek out information would make an active effort to do so after seeing a 
television commercial or hearing a radio advertisement.  Furthermore, a consumer 
must either immediately call the number or write it down for future usage.  This adds 
to the unlikelihood that a person will seek this information actively rather than 
simply asking their physician, or not asking anyone at all. 
2.  Statement to “Ask Someone Else” 
The FDA has included in its recommendations that a broadcast advertisement 
include a statement that pharmacists and/or physicians (and/or veterinarians in the 
case of animal drugs) may provide additional information to consumers.46 
This provision almost signs the doctor or pharmacist on to the advertising 
campaign of the manufacturer.  One may certainly argue that it is an essential 
function of doctors and pharmacists to respond to patient questions; however, here it 
is foremost benefiting the manufacturer.  The patient is only benefited when the 
particular therapy is appropriate for them. 
To be sure, a recent survey concluded that ninety-nine percent of physicians said 
they would prescribe or consider prescribing a drug that a patient requested.47 
3.  Statement to “Look Elsewhere” 
The FDA has recommended that manufacturers instruct the viewer of a 
consumer-directed advertisement that additional product information is provided in 
print advertisements appearing concurrently in publications that reach the exposed 
audience or in brochures located in a variety of public places.48 
This provision also provides a problem for the consumer who does not actively 
pursue information.  Even if a sufficient number of brochures were located in local 
pharmacies, doctor offices, libraries, and grocery stores, a consumer may very well 
never access them or have access to them. 
                                                                
45
Id.  An example of this practice is an advertising campaign created by ad agency Leo 
Burnett for Prozac (manufactured by Eli Lilly Co.) which doesn’t mention Prozac by name, 
but rather encourages consumers to call a toll-free number to learn more about depression and 
prescription medication for it.  See Melanie Wells, First Prozac TV Ads Air on Cable, USA 
TODAY, Sep. 15, 1998, at 2B.  The voiceovers in the commercial state “treatment that has 
worked for millions is available from your doctor.”  Id. 
46
See Draft Guidance for Industry; Consumer-Directed Broadcast Advertisements; 
Availability, 62 Fed. Reg. at 43,171. 
47
See Zuger, supra note 3, at C2. 
48
See Draft Guidance for Industry; Consumer-Directed Broadcast Advertisements; 
Availability, 62 Fed. Reg. at 43,171. 
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4.  Internet Web Page (URL) 
An Internet web page with access to the product labeling may be provided in the 
broadcast or via the toll-free telephone number.49 
The same technical objections apply here, as mentioned above, for those without 
access to the World Wide Web.  In addition, this is hardly an improvement over the 
current status since virtually all drug product information is currently available at 
multiple Internet web sites. 
V.  EFFECTS OF CONSUMER-DIRECTED PRESCRIPTION DRUG ADVERTISEMENTS ON 
THE CURRENT HEALTH CARE SYSTEM 
The advent of consumer-directed advertisements has contributed to some unique 
problems and tensions which did not exist before its inception.  It is important to 
realize the extent to which consumer-directed advertising contributes to these 
modern problems when deciding how to best deliver health care in the United States. 
A.  Enhanced Benefits/Downplayed Adverse Reactions 
Under the current regulations, an advertisement does not satisfy the “true 
statement” of the “brief summary” if it fails to present a fair balance between adverse 
reactions and information relating to effectiveness.50 
Current consumer-directed drug advertisements, like most advertisements with 
increased product sales in mind, have a tendency to focus on the benefits of the 
particular medication.  The problem with this approach in relation to prescription 
drugs is that it may create a notion to patients that the drug is safe for use specifically 
by them.  This calls to question two related issues: the physician’s role as a 
gatekeeper to dangerous medications which certain patients should not use, and the 
ability of ordinary consumers to understand risk information.  Both of these issues 
will be visited below.   
Further, the regulations fail to take into account the visual portions of an 
advertisement when suggesting “fair balance.”  The regulations clearly forbid the use 
of blatantly false or misleading statements,51 but the actors in a commercial or the 
graphic material accompanying a print advertisement are not weighed in this 
balancing.  For example, a commercial may show allergy-suffering actors enjoying 
allergy-sensitive activities while mentioning the benefits of the particular drug for all 
but the last ten seconds when the three major side effects are listed.  Since images 
have traditionally been considered speech for relevant First Amendment analysis, an 
FDA regulation addressing the role of images would be beneficial in achieving “fair 
balance.” 
This brings to question which side effects and contraindications are significant 
enough to be included in the “brief summary.” 
                                                                
49
See id. 
50
See 21 C.F.R. § 202.1(e)(5)(ii). 
51
21 C.F.R. § 202.1(e)(3)(ii). 
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B.  Scope and Quantity of Adverse Events 
Adverse drug reactions are a major cause of hospitalization, prolonged hospital 
stays, and frequently death in the United States.52  Recent studies have placed deaths 
due to adverse drug reactions among the top ten causes of death in the United 
States.53  For these reasons, public health authorities such as the FDA should 
consider regulation of the prescription drug industry more stringently. 
The current FDA “brief summary” requirements are unspecific and give 
pharmaceutical manufacturers too much control over the amount and content of 
adverse reaction and contraindication information.  The result is a downplaying of 
adverse information and an increase in patients taking unnecessary medications.  In 
addition, medications which may be necessary are never fully explained to the 
patient in understandable terms.  
Under the current regulations, manufacturers typically list the top three to five 
adverse effects of the advertised drug.  Adverse effects such as headache and nausea, 
for example, are almost always included.54  It is true that these are included because 
they are among the leading side effects of most drugs; however, it is important to 
ascertain the extent to which they may be displacing side effects which consumers 
may place more importance upon such as increased risk of stroke or blurred vision. 
Presumably the average consumer knows that headaches and nausea can be 
caused by a stressful day, spicy food, etc.  To know the extent to which a drug causes 
these frequently occurring side effects is not necessary here.  It is just important to 
realize that the inclusion of these in prescription advertisements in the “top three” 
will necessarily remove more informative risk information from the advertisement.  
It may even be appropriate to inform consumers that any foreign substance ingested 
into one’s body may cause headaches, nausea, etc.  This will allow room for more 
definitive adverse risk information so a consumer may make a more educated 
decision. 
C.  The Cost of Adverse Drug Reactions and the Impact of Advertising 
The market for prescription drugs in the United States is enormous, with annual 
drug sales exceeding eighty billion dollars.55  There is no doubt that advertising is in 
                                                                
52
See, Yvonne Bukstein, Comment, Drug Products Liability: Duty to Warn, 49 U. PITT. L. 
REV. 283 (1987). 
53
Jason Lazarou et al., Incidence of Adverse Drug Reactions in Hospitalized Patients: A 
Meta-Analysis of Prospective Studies, 279 JAMA 1200, 1202 (1998) (finding that in 1994, an 
estimated 2 million hospital patients had a serious adverse drug reaction and about 100,000 
patients had a fatal adverse drug reaction).  Although this study involved only hospitalized 
patients due to ability to record data, it is suggestive of the population at large.  Id. at 1201.  In 
fact, the researchers have admitted to being “conservative” in their approach.  Id. at 1204.  
This suggests that the out-patient problem is far worse due to a less controlled atmosphere 
involving multiple doctors without knowledge of other concurrent medications and less patient 
monitoring.  Id. 
54
For this reason, it is important to include the relevant placebo-associated risk 
information as well. 
55
IMS Global Services, Managed Care, New Product, and OTC Efforts Drive Utilization, 
(visited Dec. 2, 1997) <http://ims-america.com/communications/pr_dtcsurvey.html>. 
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the best interest of a pharmaceutical company’s bottom line.  The market for some 
new drug therapies has been estimated to be in the billions of dollars.56  Therefore, it 
is extremely attractive for manufacturers to increase their market share through 
consumer-directed advertising.57 
Adverse drug reactions contribute to an increase in the number of 
hospitalizations.58  Studies have shown that this increase in hospitalizations, due to 
adverse drug reactions, has an estimated direct cost to society of $1.56 to $4 billion 
in the United States.59 
Since the relaxing of the regulations regarding consumer-directed broadcast 
advertising,60 the industry has spent considerably more each year on consumer-
directed advertising.61  The industry spent $500 million in 1996 and $844 million in 
1997.62  This is due to the fact that it costs much more to advertise on television and 
radio than in print. 
Together with the increased costs of hospitalization and advertising, these costs 
will likely be passed on to the consumer directly through a rise in the price of drugs, 
or indirectly through insurance hikes.63  It may be possible that manufacturers would 
absorb the cost through an increase in sales;64 however, it is more likely that 
advertising would remain on the cost side of a budget and income derived would 
remain on the profit side. 
                                                                
56
See Thomas N. Riley & Jack DeRuiter, New Drugs: A Review, 23 U.S. PHARMACIST 115, 
120 (1998) (stating that the potential market for leukotriene inhibitors and antagonists for the 
treatment of asthma is estimated to be several billion dollars).  
57
When popular allergy medication Seldane (Hoechst Marion Roussel) was removed from 
the market in 1997, other manufacturers raced to advertise their allergy medications to 
potential consumers who could no longer acquire Seldane.  See, Yumiko Ono, Drug Makers 
Try to Win Over Seldane Users, WALL ST. J., Jan. 31, 1997, at B1.  
58
See Lazarou et al., supra note 54 at 1202. 
59
See Classen et al., Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, 
Extra Costs, and Attributable Mortality, 277 JAMA 301, 304 (1997);  Bates et al., The Costs 
of Adverse Drug Events in Hospitalized Patients, 277 JAMA 307, 311 (1997). 
60
See Pushing Ethical Pharmaceuticals Direct to the Public, supra note 40, at 921. 
61
Id. 
62
Id. 
63
Id. (stating that whether public or private insurance foots a nation’s drug bill, in the end 
it is always the public who pays). 
64
See Steven W. Kopp, Direct-to-Consumer Advertising and Consumer Prescription 
Prices, 30 DRUG INFO. J. 59, 61 (1996) (stating that consumer-directed advertising tends to 
lower the price of advertised drugs relative to other drugs.); but cf. Hunt, supra note 2 at 11.  
(stating that this is in line with the dual-stage economic theory which forces all drug retailers 
to price advertised drugs competitively with other retailers.  Also, retailers may offset prices 
by taking a loss on advertised drugs and increasing the prices on other drugs.  Therefore, the 
impact of advertising on the overall prices of prescription drugs is still not known).  
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Therefore, the current FDA regulatory system fosters a drug market where the 
drug product made by a manufacturer with an enormous advertising budget may 
displace a product with considerable cost savings and a superior therapeutic profile. 
By making the FDA regulations more stringent, there is no additional cost to the 
manufacturer over present conditions.  The manufacturers already have the required 
information on adverse events.  In order to get prescription drug approval from the 
FDA, all manufacturers must accumulate clinical trial information that must be 
included in the application for a new drug (NDA).65 
However, if a more stringent policy leads to a decrease in sales, many 
manufacturers may make claims that their freedom of expression is being curtailed.  
Whenever regulations involving restriction of speech are proposed, the First 
Amendment necessarily comes into play.  The speech of concern here is certainly 
commercial speech since the main purpose of the speech is to increase revenue.66  
The Supreme Court has held that a lesser degree of free speech protection applies to 
purely commercial speech.67  Furthermore, if the goal of a regulation that prohibits or 
curtails commercial speech is legitimately to protect consumers’ public health, then 
it will more likely withstand a constitutional challenge. 
Here, the FDA has a legitimate interest in protecting the public health.  There is 
no doubt that the preservation of public health is among the most important functions 
of government.68  Therefore, a court applying the Supreme Court’s four-part test 
from Central Hudson Gas & Electric Corp. v. Public Service Commission of New 
York and 44 Liquormart, Inc. v. Rhode Island69 would likely find that a substantial 
legitimate governmental interest exists for which this type of commercial speech 
may be regulated.  Strengthening FDA regulations to encourage disclosure of the 
dangerous propensities of drugs also directly advances the FDA’s interest in 
protecting the public from dangerous drugs.  For these reasons, a Constitutional 
challenge under the First Amendment would not likely be successful. 
                                                                
65
The FDA requires the accumulation of very specific clinical trial information as part of 
the prescription drug approval process. 
66
See Valentine v. Chrestensen, 316 U.S. 52, 54 (1942).  The Court defined commercial 
speech as speech towards endorsing and selling a particular product. 
67
See 44 Liquormart, Inc. v. Rhode Island, 517 U.S. 484, 498 (1996).  The Court slightly 
changed the four-part test from Central Hudson Gas & Elec. Corp. v. Public Serv. Comm’n of 
N.Y., 447 U.S. 557 (1980) that should be used in determining if a commercial speech 
restriction can be upheld: (1) Does commercial speech concern lawful activity and is it 
otherwise not misleading?; (2) Is asserted governmental interest in regulating interest 
substantial?; (3) Does regulation of commercial speech directly advance governmental 
interest?; and (4) is regulation no more expansive than necessary to serve governmental 
interest?  Id. at 528.  But cf. Virginia State Bd. of Pharmacy, 425 U.S. 761.  The Court 
indicated that “speech does not lose its First Amendment protection because money is spent to 
project it, as in a paid advertisement of one form or another.”  Id. 
68
See Jacobsen v. Massachusetts, 197 U.S. 11, 25 (1905).  The Court states that the 
protection and preservation of the public health is among the most important duties of [state] 
government.  Id.  Here, the federal government (FDA) is vested with the duty to protect 
consumers in the case of drug advertising because advertising occurs on a national level.  Id. 
69See 44 Liquormart, Inc., 517 U.S. at 498. 
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It may become apparent that more substantial listing of adverse reactions is so 
burdensome and impracticable on manufacturers that it effectively denies the right to 
advertise in certain mediums (i.e. broadcast).  It is necessary to realize that there are 
other alternative means available and that all advertising would not be banned.  Any 
means that would disclose the required adverse reactions in an understandable way 
should be permitted.  This may require utilizing new forms of consumer-directed 
prescription advertising such as the “info-mercial.” 
It is important to note here again that the FDA should not ban this type of 
commercial speech, but rather regulate the quality and context of the information that 
is disseminated in a way that balances the manufacturer’s right to advertise and the 
governmental (FDA) interest in protecting public health. 
More stringent regulations will likely affect the content and appearance of drug 
advertisements and effectively deny some manufacturers the right to advertise their 
product.  By requiring manufacturers to list a minimum percentile of side effects, for 
more “dangerous” drugs this may include upwards of forty side effects.  
Manufacturers will have to decide if advertising will actually benefit their product 
sales or hurt them. 
D.  Deterrence 
A strong argument may be made that certain patients will actually be deterred 
from taking necessary medications because of fear of disclosed adverse effects.  It is 
logical to think that consumers bombarded with adverse drug reactions may elect to 
not participate in a particular drug therapy.70  This would be primarily from fear that 
they would be among the percentage of sufferers of a particular adverse reaction.  
This would in turn directly affect the public health; arguably, worse than the above 
mentioned effects from inadequate adverse reaction information. 
Physicians are certainly the best suited to determine the appropriateness of 
prescription medications for their patients.  It is difficult to strike a balance between 
this thinking and the allowance of consumer-directed advertising of prescription 
drugs.  If patients began refusing, out of fear, prescriptions ordered by physicians, 
there would undoubtedly be a decrease in the overall public health status.  This begs 
the question of whether consumers are better off being over-medicated or under-
medicated? 
It would be reasonable to assume that patients who are prescribed medication that 
is deemed “life-saving” or absolutely necessary to the preservation of their current 
health status would follow their doctor’s orders and take the medication regardless of 
adverse events learned through advertising.  For example, this would include 
medication for high blood pressure or diabetes (interestingly, conditions for which 
treatments are not usually advertised since they are not “self-diagnosing” 
conditions).  The problem of deterrence lies most heavily with precisely the type of 
medications which seem to be frequently advertised. 
Keeping with the above example (assuming a patient will most always take 
necessary blood pressure-reducing medication), a patient who avoids an 
antihistamine/decongestant product for treating their seasonal allergies because they 
                                                                
70
See Yumiko Ono, More Drug Ads Ticking Off List of Health Risks Expected on TV, 
WALL ST. J., Aug. 11, 1997, at B6 (stating that commercials are long, wordy, and packed with 
scary-sounding medical warnings that could turn off consumers). 
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learn it may affect their blood pressure is better off with allergy symptoms than those 
of uncontrolled blood pressure.  In this patient, being under-medicated is preferred.  
While this may not always be the case, it is illustrative of how a patient with all 
necessary information may be better equipped to ensure their own health status.  The 
deterrent argument assumes that consumers are unable to accurately assess their own 
risk.  It is unclear whether the average consumer can truly appreciate a risk that they 
do not fully understand.71  However, by not disclosing full information, the consumer 
is denied the opportunity to understand and the opportunity to make a rational 
decision regarding their own personal well being. 
Consumers flooded with adverse reaction information may be initially deterred at 
the onset of such a proposed regulation.  This effect would likely be only temporary.  
As consumers begin to learn that all drugs have adverse profiles and begin to learn 
how to assess and compare adverse drug information, the end result will be a patient 
who is more informed and active in their own health decisions. 
E.  The Strain on the Doctor-Patient Relationship 
There is no doubt that the nature of the doctor-patient relationship has changed 
over the last few decades.72  The physician of the past was rarely questioned by the 
patient, even when the doctor had clearly erred.  Today, with more consumers armed 
with available health information, doctors are frequently questioned and patients are 
taking a more active role in their treatment.  While not true with all patients, many 
“active” patients are turning the tables and converting the doctor into a more 
“passive” health care provider.  Upon arrival at an appointment with a physician, 
active patients have what they believe to be an extensive knowledge of their 
condition.  In addition, active patients present the physician with an agenda of what 
type of health care they demand and how it will be delivered.  The physician is left in 
a passive role answering questions and when applicable, dispelling false notions. 
An active patient, and all patients, undoubtedly deserve access to health 
information.  Arguably, consumer-directed advertising is a part of this valuable 
consumer information base.  However, if this information is biased or in some way 
incomplete, the end result tends to put the patient in a worse position than with no 
information at all.73  By allowing prescription drug advertisements which are 
unbalanced in relation to the good and bad aspects of a medication, the FDA is 
                                                                
71
This is an important reason why consumer-directed advertisements should be in “patient 
language” rather than in scientific terminology. 
72
“Ever-increasing complexity and costs have brought about vast changes in the delivery 
of medical services.  Today, most would not recognize Norman Rockwell’s portrait of the 
family doctor.”  Dunn v. Praiss, 656 A.2d 413, 415 (N.J. 1995); Emanuel and Dubler have 
expressed the fundamental elements of the ideal physician-patient relationship embodied in 
our intuitions and common to ethical analyses and legal standards as “the six C’s” choice, 
competence, communication, compassion, continuity, and (no) conflict of interest.  Ezekiel J. 
Emanuel & Nancy Neveloff Dubler, Preserving the Physician-Patient Relationship in the Era 
of Managed Care, 273 JAMA 323, 324-25 (1995). 
73
See STEPHEN FRIED, BITTER PILLS:  INSIDE THE HAZARDOUS WORLD OF LEGAL DRUGS 
299-301 (stating that with such consumer-directed advertising, the line between over-the-
counter and prescribed drugs has dimmed and that patients begin to view all advertised drugs 
as innocuous). 
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fostering an atmosphere in which all patients may be getting an inadequate 
introduction to prescription drugs. 
With the advent of managed care, many physicians have had to cut back their 
actual amount of time with each patient.  This is an unfortunate effect of managed 
care, but nonetheless a reality.  Nurses and other support staff have commonly 
relieved the doctor of some preliminary office visit functions and “prepare” the 
patient so the doctor can quickly examine the patient.  When doctors must spend a 
portion of this short time responding to inquiries made regarding possible drug 
therapies that the active patient suggests, the overall health of the patient may be 
compromised.74  The time spent regarding these therapies directly takes away from 
the doctor’s active role in treating the patient.75 
Arguably, it is part of the physician’s role to respond to questions as the patient’s 
health care provider.  In excess, this passive role is likely new for most physicians.  
Consumer-directed advertising puts an additional burden on physicians.  Most 
physicians will have to learn more about every drug to adequately assess its 
appropriateness for their patient.  For example, if a physician has a “favorite” drug to 
prescribe for a particular condition (for any number of reasons—efficacy, cost, etc.) 
and a patient inquires about another specific drug that the doctor is less familiar with, 
the doctor must either look up the prescribing information about that drug or 
dissatisfy the patient by denying the medication request.  The third possibility is for 
the physician to prescribe the drug without complete knowledge of its efficacy.  The 
first possibility imposes additional responsibility and time constraints on the 
physician; the second, a dissatisfied patient; and the third, increased physician 
liability. 
The manufacturers’ dependency on physicians to play an active role in fulfilling 
disclosure requirements and shifting liability is demonstrated by this point.  Drug 
                                                                
74
See Crigger, supra note 2, at 47 (stating that ethicists at the Medical College of 
Wisconsin Bioethics Division noted that the problem with the increase in patient information 
is “that conversations about advertised medications must take place during the ever-dwindling 
amount of time doctors can actually spend with individual patients”). 
75
In a recent survey of almost 5,000 physicians questioned about consumer-directed 
advertising of prescription drugs, the following results were noted: (1) more than 60% of 
physicians said that they would like to see consumer-directed advertising stopped or 
decreased; (2) nearly 40% said they felt that the consumer audience in general lacks adequate 
knowledge about pharmaceuticals to understand the advertisements; (3) almost one-third said 
that consumer-directed advertisements are misleading because they fail to provide adequate 
adverse information such as side effects; (4) approximately 20% feel that consumer-directed 
advertisements bring disharmony to the doctor-patient relationship and that they spend 
excessive time justifying their prescribing decision and why a requested drug is inappropriate 
for the patient; and, (5) more than 40% reported an increase in the number of brand name 
requests since consumer-directed advertising began.  Marjorie Kauffman Sherr & Donna 
Cutrone Hoffman, Physicians—Gatekeepers to DTC Success, PHARMACEUTICAL EXECUTIVE, 
Oct. 1997, at 56.  But cf. Stuart Elliott, Take Two Direct Sales Pitches for Prescription Drugs 
and Call Your Pollster in the Morning, N.Y. TIMES, Jul. 29, 1998, at D2 (reviewing consumer 
opinion of consumer-directed drugs and stating that consumer opinion toward such advertising 
is generally favorable.  However, the same survey also revealed that consumers find the 
advertisements lacking in clarity and usefulness, and are concerned that these advertisements 
diminish prescription drugs by likening them to heavily advertised packaged goods).  
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manufacturers have defended consumer-directed advertising as providing important 
information that empowers patients and enhances choice.  Patients are also protected 
from imprudently using medications by the fact that physicians control access 
through prescriptions.76 
VI.  RECOMMENDATIONS FOR FDA REGULATION IMPROVEMENT 
A patient undergoing surgery is entitled to full access to a range of information 
before electing to undergo the procedure under traditional principles of informed 
consent.  Courts have defended an individual’s right to determine the appropriateness 
of medical treatment,77 and the selection of drug therapy should not be construed 
differently.  Although this is not an issue of informed consent, it may be helpful to 
think of it in a similar framework.  The patient must be able to accurately assess risk 
and benefit information in order to decide if a particular drug therapy is appropriate 
for themselves. 
Risk versus benefit analysis seems to be present in many aspects of everyday life.  
For example, one may unconsciously weigh the risks of jaywalking against the 
benefit of inconvenience and time saved by not having to walk to the intersection to 
cross the street.  In this example, it is highly likely that a reasonable person can 
assess the various risks present (i.e. getting hit by a car, getting arrested for 
jaywalking, etc.).  In the case of prescription drugs, however, consumers are much 
more likely to have difficulty assessing the technical scientific risk information 
associated with a drug and weighing it against the drug’s claimed benefits.  In other 
words, consumers need more assistance and protection in making reasonable health 
care decisions, particularly in the area of prescription drugs.  Presumably, even the 
most well-educated Americans, outside of medical fields, can not fully understand 
this type of scientific data.  With current social problems such as the high rate of 
illiteracy, consumer protection is especially important in this area, and the FDA 
should maximize its authority to regulate the prescription drug market. 
A.  Standard Percentile 
Currently, there is no requirement for the scope or quantity of adverse reaction 
information included in consumer-directed advertisements.  The standard practice 
seems to be to list the top three; however, this may be grossly inadequate in the case 
of drugs with more “dangerous” adverse reaction profiles. 
It is conceded that a complete list of adverse reactions for a drug is impracticable 
for a number of reasons.  First, reactions occurring in infinitesimally small 
percentages of the population would unlikely deter or usefully educate even the most 
worrisome consumer.  Also, from a practical viewpoint, if the FDA is to allow the 
practice of consumer-directed advertisements to continue (especially in the broadcast 
medium), the advertisements will need to allot time to establish the benefits of the 
stated drug in accordance with the “fair balance” requirements stated above. 
                                                                
76
See Crigger, supra note 2, at 47. 
77
See Estate of Behringer v. Medical Ctr., 592 A.2d 1251, 1278 (N.J. Super. Ct. Law Div. 
1991) (“The purpose of this legal requirement is to protect each person’s right to self-
determination in matters of medical treatment. . . .  Medical information or a risk of a medical 
procedure is material when a reasonable patient would be likely to attach significance to it in 
deciding whether or not to submit to the treatment.”). 
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The FDA should consider requiring manufacturers to list all adverse events 
occurring in a standard percentile and above in the clinical test population.  This 
figure would have to be researched and determined by the FDA in accordance with 
available adverse drug statistics.  This uniform number would allow a patient to 
become comfortable with assessing adverse information and to accurately make 
comparison judgments between related medications.  Patients will then be able to 
make a calculated risk decision regarding a major part of their health care.  It is 
conceded that this risk decision would also involve other considerations such as (1) 
the nature of the particular risk involved and the placebo-associated risk percentage; 
(2) the perceived benefit of the drug therapy;78 and (3) the cost of each of the risks 
and benefits.  Also to a lesser extent, the professional advice of the prescriber, or 
from friends or family experiencing similar problems, may affect one’s judgment. 
B.  Patient-Friendly Language 
It is imperative that the disclosure of adverse events be in languages79 that the 
ordinary consumer can understand.80  As stated above, it is doubtful that increased 
disclosure will benefit the public health if not conveyed in a way that makes the 
additional information understandable.  This presents no additional burden on the 
manufacturer, but rather just a simple translation of a scientific drug side effect to a 
lay person definition. 
C.  An Illustration 
To illustrate the practical effects of this proposed standard percentile in patient 
friendly language, the adverse reactions from several recent broadcast 
advertisements will be compared with the adverse reactions occurring in one percent 
and greater of the clinical test population in the table below.81 
 
                                                                
78
For example, a consumer may risk seemingly benign side effects such as headache or 
nausea in order to prevent a heart attack, but may not be willing to endure those same side 
effects in order to relieve a runny nose. 
79
See Pushing Ethical Pharmaceuticals Direct to the Public, supra note 40, at 921 (stating 
that drug information is currently not written for the general reader with terms like HMG-
CoA, AST, ALT, and 3-alpha-hydroxy metabolites appearing in such advertisements). 
80
The FDA has recognized that consumers don’t have the technical background to 
understand the professional labeling that accompanies a drug product and recommends the use 
of “FDA-approved” labeling.  “FDA-approved” labeling is labeling intended to be understood 
by the patient to help them use their medication more effectively and safely.  However, the 
quantity or scope of information that would meet this recommendation is not explained by the 
FDA.  Direct-to-Consumer Promotion, 61 Fed. Reg. 24,314, 24,315 (1996). 
81
Advertised information for Valtrex from: Valtrex commercial (Discovery Channel 
broadcast, Nov. 13, 1998).  (Valtrex commercial is promoting Valtrex for treatment of genital 
herpes with 500mg twice-daily dosage only.  Only that adverse reaction information is 
required in accordance with FDA regulations, so only that information will be included here); 
advertised information for Nasonex from: Nasonex commercial (Discovery Channel 
broadcast, Nov. 13, 1998); adverse drug reaction information from: Valtrex product 
information (Glaxo Wellcome) & Nasonex product information (Schering Corporation). 
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Valtrex Nasonex
Description -(valacyclovir hydrochloride, Glaxo 
Wellcome, Inc.)-indicated for the 
treatment of genital herpes.
-(mometasone furoate 
monohydrate, Schering 
Corporation)-indicated for 
treatment of nasal symptoms of 
allergic reactions.
Advertised Adverse Drug 
Reactions
-nausea
-headache
-headache
-viral infection
-sore throat
-nose bleed
-coughing
Adverse Drug Reactions 
(Occurring in 1% or 
Greater of Clinical Test 
Population) & [Placebo]
-nausea (6%)[8%]
-headache (17%)[14%]
-vomiting (1%)[<1%]
-dizziness (2%)[3%]
-abdominal pain (3%)[3%] 
-dysmenorrhea (painful                
menstruation) (1%)[<1%]
-arthralgia (joint pain) (1%)[<1%]
-depression (0%)[<1%]
-headache (26%)[22%]
-viral infection (14%)[11%]
-sore throat (12%)[10%]
-nose bleed (11%)[6%]
-coughing (7%)[6%]
-upper respiratory infect. (6%)[2%]
-dysmennorhea(painful 
menstruation) (5%)[3%]
-musculoskeletal pain (5%)[3%]
-sinusitis (sinus inflammation) 
(5%)[3%]
-(Occurring in pts. between 5% and 
2% and more frequently than 
placebo: arthralgia(joint pain), 
asthma, bronchitis(chest 
inflammation), chest pain, 
conjunctivitis(eye inflammation), 
diarrhea, dyspepsia(indigestion), 
earache, flu-like symptoms, 
myalgia(muscle pain), nausea, 
rhinitis(nasal inflammation) 
 
 
The inclusion of placebo-related risk information is an important element in 
consumer-directed information.  This allows the patient to assess their risk of a 
particular adverse reaction in the absence of the medication.  At first, it may seem 
that the relative risk of many of the above listed adverse reactions are not 
significantly higher than the placebo percentage.  However, the test population 
(including the placebo group) of the clinical trial consists of individuals with the 
particular condition that is attempting to be cured.  For example, the risk of nose 
bleed from using Nasonex nose spray is eleven percent compared with a six percent 
risk in the placebo group.  This may not seem like a significant increase, but patients 
using the spray are experiencing the side effect at a rate that is nearly double their 
usual risk. 
With the inclusion of the above product information in addition to what is 
currently being disclosed, consumers will have a more complete framework within 
which to make rational health care decisions.  It benefits the public health to have a 
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federally regulated standard for all broadcast advertisements rather than to allow 
manufacturers with a largely financial interest to determine the amount of adverse 
drug information included. 
VII.  CONCLUSION 
The prescription drug industry and the nature of advertising have changed 
dramatically in the sixty years that have passed since the FDA developed regulations 
that controlled advertising in the industry.  The current FDA regulations regarding 
prescription drug advertising need to be supplemented or amended to include for 
more stringent requirements when prescription drugs are advertised directly to 
consumers. 
A standard percentile, over which all adverse reactions must be reported by all 
manufacturers, is needed to ensure safety and uniformity within the prescription drug 
industry. 
Information provided to consumers about prescription drugs must be complete 
and unbiased.  Additionally, the language used in such advertisements must be in 
terms that ordinary consumers can understand to allow them to make rational health 
care decisions for themselves consistent with traditional principles of informed 
consent. 
This increased regulation on the information provided by pharmaceutical 
companies directly to the public will have the effect of decreasing unwanted drug 
side effects because the patient will know in advance their statistical risk of such an 
adverse event.  The consumer may then decide, together with doctor 
recommendations, whether a particular drug therapy is appropriate for themselves 
and be prepared to accept adverse reactions should they occur. 
 
